Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 35 entries
Sorted by: Best Match Show Resources per page
In JNMA 100 years ago: the 1908 annual meeting.

Journal of the National Medical Association

Savitt TL.
PMID: 20191929
J Natl Med Assoc. 2010 Feb;102(2):140-3. doi: 10.1016/s0027-9684(15)30516-2.

No abstract available.

Cite
Savitt TL. In JNMA 100 years ago: the 1908 annual meeting. J Natl Med Assoc. 2010;102(2):140-3doi: 10.1016/s0027-9684(15)30516-2.
Savitt, T. L. (2010). In JNMA 100 years ago: the 1908 annual meeting. Journal of the National Medical Association, 102(2), 140-3. https://doi.org/10.1016/s0027-9684(15)30516-2
Savitt, Todd L. "In JNMA 100 years ago: the 1908 annual meeting." Journal of the National Medical Association vol. 102,2 (2010): 140-3. doi: https://doi.org/10.1016/s0027-9684(15)30516-2
Savitt TL. In JNMA 100 years ago: the 1908 annual meeting. J Natl Med Assoc. 2010 Feb;102(2):140-3. doi: 10.1016/s0027-9684(15)30516-2. PMID: 20191929.
Copy Download .nbib Format: NLM
eIF5 is a dual function GAP and GDI for eukaryotic translational control.

Small GTPases

Jennings MD, Pavitt GD.
PMID: 21686265
Small GTPases. 2010 Sep;1(2):118-123. doi: 10.4161/sgtp.1.2.13783.

We recently showed in a publication in Nature that the eukaryotic translation initiation factor eIF5 has a second regulatory function and is a GDI (GDP dissociation inhibitor) in addition to its previously characterized role as a GAP (GTPase accelerating...

Cite
Jennings MD, Pavitt GD. eIF5 is a dual function GAP and GDI for eukaryotic translational control. Small GTPases. 2010;1(2):118-123doi: 10.4161/sgtp.1.2.13783.
Jennings, M. D., & Pavitt, G. D. (2010). eIF5 is a dual function GAP and GDI for eukaryotic translational control. Small GTPases, 1(2), 118-123. https://doi.org/10.4161/sgtp.1.2.13783
Jennings, Martin D, and Pavitt, Graham D. "eIF5 is a dual function GAP and GDI for eukaryotic translational control." Small GTPases vol. 1,2 (2010): 118-123. doi: https://doi.org/10.4161/sgtp.1.2.13783
Jennings MD, Pavitt GD. eIF5 is a dual function GAP and GDI for eukaryotic translational control. Small GTPases. 2010 Sep;1(2):118-123. doi: 10.4161/sgtp.1.2.13783. PMID: 21686265; PMCID: PMC3116597.
Copy Download .nbib Format: NLM
Levodopa-induced dyskinesias in mitochondrial membrane protein-associated neurodegeneration.

Neurology. Clinical practice

Savitt D, Jankovic J.
PMID: 30859014
Neurol Clin Pract. 2019 Feb;9(1):e7-e9. doi: 10.1212/CPJ.0000000000000577.

No abstract available.

Cite
Savitt D, Jankovic J. Levodopa-induced dyskinesias in mitochondrial membrane protein-associated neurodegeneration. Neurol Clin Pract. 2019;9(1):e7-e9doi: 10.1212/CPJ.0000000000000577.
Savitt, D., & Jankovic, J. (2019). Levodopa-induced dyskinesias in mitochondrial membrane protein-associated neurodegeneration. Neurology. Clinical practice, 9(1), e7-e9. https://doi.org/10.1212/CPJ.0000000000000577
Savitt, Daniel, and Jankovic, Joseph. "Levodopa-induced dyskinesias in mitochondrial membrane protein-associated neurodegeneration." Neurology. Clinical practice vol. 9,1 (2019): e7-e9. doi: https://doi.org/10.1212/CPJ.0000000000000577
Savitt D, Jankovic J. Levodopa-induced dyskinesias in mitochondrial membrane protein-associated neurodegeneration. Neurol Clin Pract. 2019 Feb;9(1):e7-e9. doi: 10.1212/CPJ.0000000000000577. PMID: 30859014; PMCID: PMC6382374.
Copy Download .nbib Format: NLM
Women with chronic constipation have more bothersome urogenital symptoms.

Techniques in coloproctology

Ortega MV, Kim Y, Hung K, James K, Savitt L, Von Bargen E, Bordeianou LG, Weinstein MM.
PMID: 34820751
Tech Coloproctol. 2021 Nov 24; doi: 10.1007/s10151-021-02518-4. Epub 2021 Nov 24.

BACKGROUND: The aim of our study was to characterize urogenital symptoms in women with and without constipation, and by severity of constipation.METHODS: This was a retrospective cohort study conducted at a pelvic floor disorder center in a tertiary healthcare...

Cite
Ortega MV, Kim Y, Hung K, et al. Women with chronic constipation have more bothersome urogenital symptoms. Tech Coloproctol. 2021;doi: 10.1007/s10151-021-02518-4.
Ortega, M. V., Kim, Y., Hung, K., James, K., Savitt, L., Von Bargen, E., Bordeianou, L. G., & Weinstein, M. M. (2021). Women with chronic constipation have more bothersome urogenital symptoms. Techniques in coloproctology, . https://doi.org/10.1007/s10151-021-02518-4
Ortega, M V, et al. "Women with chronic constipation have more bothersome urogenital symptoms." Techniques in coloproctology vol. (2021). doi: https://doi.org/10.1007/s10151-021-02518-4
Ortega MV, Kim Y, Hung K, James K, Savitt L, Von Bargen E, Bordeianou LG, Weinstein MM. Women with chronic constipation have more bothersome urogenital symptoms. Tech Coloproctol. 2021 Nov 24; doi: 10.1007/s10151-021-02518-4. Epub 2021 Nov 24. PMID: 34820751.
Copy Download .nbib Format: NLM
Comparison of Mini-Mental State Examination and Montreal Cognitive Assessment Ratings Across Levels of Parkinson's Disease Severity.

Journal of Parkinson's disease

Snyder A, Gruber-Baldini AL, Rainer von Coelln F, Savitt JM, Reich SG, Armstrong MJ, Shulman LM, Wiers RW, Bartholow BD.
PMID: 34366371
J Parkinsons Dis. 2021;11(4):1995-2003. doi: 10.3233/JPD-212705.

BACKGROUND: Cognitive impairment (CI) is common in Parkinson's disease (PD) and an important cause of disability. Screening facilitates early detection of CI and has implications for management. Preclinical disability is when patients have functional limitations but maintain independence through...

Cite
Snyder A, Gruber-Baldini AL, Rainer von Coelln F, et al. Comparison of Mini-Mental State Examination and Montreal Cognitive Assessment Ratings Across Levels of Parkinson's Disease Severity. J Parkinsons Dis. 2021;11(4):1995-2003doi: 10.3233/JPD-212705.
Snyder, A., Gruber-Baldini, A. L., Rainer von Coelln, F., Savitt, J. M., Reich, S. G., Armstrong, M. J., Shulman, L. M., Wiers, R. W., & Bartholow, B. D. (2021). Comparison of Mini-Mental State Examination and Montreal Cognitive Assessment Ratings Across Levels of Parkinson's Disease Severity. Journal of Parkinson's disease, 11(4), 1995-2003. https://doi.org/10.3233/JPD-212705
Snyder, Allison, et al. "Comparison of Mini-Mental State Examination and Montreal Cognitive Assessment Ratings Across Levels of Parkinson's Disease Severity." Journal of Parkinson's disease vol. 11,4 (2021): 1995-2003. doi: https://doi.org/10.3233/JPD-212705
Snyder A, Gruber-Baldini AL, Rainer von Coelln F, Savitt JM, Reich SG, Armstrong MJ, Shulman LM, Wiers RW, Bartholow BD. Comparison of Mini-Mental State Examination and Montreal Cognitive Assessment Ratings Across Levels of Parkinson's Disease Severity. J Parkinsons Dis. 2021;11(4):1995-2003. doi: 10.3233/JPD-212705. PMID: 34366371.
Copy Download .nbib Format: NLM
Living and Leaving Life on One's Own Terms: Certain Legal Rights of Older Adults and Persons with Disabilities.

Topics in stroke rehabilitation

Slavitt EB, LaBant TM.
PMID: 27620152
Top Stroke Rehabil. 1996 Jan;2(4):44-53. doi: 10.1080/10749357.1996.11754092.

While attention has been focused on granting equal rights based on race, religion, and gender, the rights of older and disabled persons have been overlooked for many years. Existing laws were of limited scope or were not enforced. However,...

Cite
Slavitt EB, LaBant TM. Living and Leaving Life on One's Own Terms: Certain Legal Rights of Older Adults and Persons with Disabilities. Top Stroke Rehabil. 1996;2(4):44-53doi: 10.1080/10749357.1996.11754092.
Slavitt, E. B., & LaBant, T. M. (1996). Living and Leaving Life on One's Own Terms: Certain Legal Rights of Older Adults and Persons with Disabilities. Topics in stroke rehabilitation, 2(4), 44-53. https://doi.org/10.1080/10749357.1996.11754092
Slavitt, E B, and LaBant, T M. "Living and Leaving Life on One's Own Terms: Certain Legal Rights of Older Adults and Persons with Disabilities." Topics in stroke rehabilitation vol. 2,4 (1996): 44-53. doi: https://doi.org/10.1080/10749357.1996.11754092
Slavitt EB, LaBant TM. Living and Leaving Life on One's Own Terms: Certain Legal Rights of Older Adults and Persons with Disabilities. Top Stroke Rehabil. 1996 Jan;2(4):44-53. doi: 10.1080/10749357.1996.11754092. PMID: 27620152.
Copy Download .nbib Format: NLM
In Vitro-Administered Dexamethasone Suppresses T Cell Function With Reversal by Interleukin-7 in Coronavirus Disease 2019.

Critical care explorations

Mazer MB, Davitt E, Turnbull IR, Caldwell CC, Brakenridge SC, Remy KE, Hotchkiss RS.
PMID: 33834168
Crit Care Explor. 2021 Apr 02;3(4):e0378. doi: 10.1097/CCE.0000000000000378. eCollection 2021 Apr.

OBJECTIVES: Corticosteroid therapy has become standard of care therapy for hospitalized patients infected with the severe acute respiratory syndrome coronavirus-2 global pandemic-causing virus. Whereas systemic inflammation is a notably important feature in coronavirus disease 2019 pathogenesis, adaptive immune suppression...

Cite
Mazer MB, Davitt E, Turnbull IR, et al. In Vitro-Administered Dexamethasone Suppresses T Cell Function With Reversal by Interleukin-7 in Coronavirus Disease 2019. Crit Care Explor. 2021;3(4):e0378doi: 10.1097/CCE.0000000000000378.
Mazer, M. B., Davitt, E., Turnbull, I. R., Caldwell, C. C., Brakenridge, S. C., Remy, K. E., & Hotchkiss, R. S. (2021). In Vitro-Administered Dexamethasone Suppresses T Cell Function With Reversal by Interleukin-7 in Coronavirus Disease 2019. Critical care explorations, 3(4), e0378. https://doi.org/10.1097/CCE.0000000000000378
Mazer, Monty B, et al. "In Vitro-Administered Dexamethasone Suppresses T Cell Function With Reversal by Interleukin-7 in Coronavirus Disease 2019." Critical care explorations vol. 3,4 (2021): e0378. doi: https://doi.org/10.1097/CCE.0000000000000378
Mazer MB, Davitt E, Turnbull IR, Caldwell CC, Brakenridge SC, Remy KE, Hotchkiss RS. In Vitro-Administered Dexamethasone Suppresses T Cell Function With Reversal by Interleukin-7 in Coronavirus Disease 2019. Crit Care Explor. 2021 Apr 02;3(4):e0378. doi: 10.1097/CCE.0000000000000378. eCollection 2021 Apr. PMID: 33834168; PMCID: PMC8021361.
Copy Download .nbib Format: NLM
American Association for the History of Medicine: Report of the Seventy-fourth Annual Meeting.

Bulletin of the history of medicine

Savitt TL.
PMID: 11740119
Bull Hist Med. 2001;75(3):535-551. doi: 10.1353/bhm.2001.0148.

No abstract available.

Cite
Savitt TL. American Association for the History of Medicine: Report of the Seventy-fourth Annual Meeting. Bull Hist Med. 2001;75(3):535-551doi: 10.1353/bhm.2001.0148.
Savitt, T. L. (2001). American Association for the History of Medicine: Report of the Seventy-fourth Annual Meeting. Bulletin of the history of medicine, 75(3), 535-551. https://doi.org/10.1353/bhm.2001.0148
Savitt, Todd Lee. "American Association for the History of Medicine: Report of the Seventy-fourth Annual Meeting." Bulletin of the history of medicine vol. 75,3 (2001): 535-551. doi: https://doi.org/10.1353/bhm.2001.0148
Savitt TL. American Association for the History of Medicine: Report of the Seventy-fourth Annual Meeting. Bull Hist Med. 2001;75(3):535-551. doi: 10.1353/bhm.2001.0148. PMID: 11740119.
Copy Download .nbib Format: NLM
Effects of risperidone on auditory event-related potentials in schizophrenia.

The international journal of neuropsychopharmacology

Umbricht D, Javitt D, Novak G, Bates J, Pollack S, Lieberman J, Kane J.
PMID: 11285146
Int J Neuropsychopharmacol. 1999 Dec;2(4):299-304. doi: 10.1017/S1461145799001595.

Schizophrenia is associated with cognitive deficits for which treatments remain elusive. The effects of risperidone (an antipsychotic differing in some of its pharmacological properties from typical agents) on cognitive deficits have not been extensively investigated. Mismatch negativity (MMN), N2...

Cite
Umbricht D, Javitt D, Novak G, et al. Effects of risperidone on auditory event-related potentials in schizophrenia. Int J Neuropsychopharmacol. 1999;2(4):299-304doi: 10.1017/S1461145799001595.
Umbricht, D., Javitt, D., Novak, G., Bates, J., Pollack, S., Lieberman, J., & Kane, J. (1999). Effects of risperidone on auditory event-related potentials in schizophrenia. The international journal of neuropsychopharmacology, 2(4), 299-304. https://doi.org/10.1017/S1461145799001595
Umbricht, Daniel, et al. "Effects of risperidone on auditory event-related potentials in schizophrenia." The international journal of neuropsychopharmacology vol. 2,4 (1999): 299-304. doi: https://doi.org/10.1017/S1461145799001595
Umbricht D, Javitt D, Novak G, Bates J, Pollack S, Lieberman J, Kane J. Effects of risperidone on auditory event-related potentials in schizophrenia. Int J Neuropsychopharmacol. 1999 Dec;2(4):299-304. doi: 10.1017/S1461145799001595. PMID: 11285146.
Copy Download .nbib Format: NLM
Learning About Sickle Cell: The Patient in Early Sickle Cell Disease Case Reports, 1910-1933.

Journal of the National Medical Association

Savitt TL.
PMID: 26744113
J Natl Med Assoc. Summer 2014;106(1):31-41. doi: 10.1016/S0027-9684(15)30068-7.

Case reports of sickle cell disease (SCD) from its discovery in 1910 to 1933 provide glimpses into the disease's impact on patients and families. Attending physicians, trying to understand the pathophysiology of and treatments for this newly recognized disease,...

Cite
Savitt TL. Learning About Sickle Cell: The Patient in Early Sickle Cell Disease Case Reports, 1910-1933. J Natl Med Assoc. 0;106(1):31-41doi: 10.1016/S0027-9684(15)30068-7.
Savitt, T. L. (0). Learning About Sickle Cell: The Patient in Early Sickle Cell Disease Case Reports, 1910-1933. Journal of the National Medical Association, 106(1), 31-41. https://doi.org/10.1016/S0027-9684(15)30068-7
Savitt, Todd L. "Learning About Sickle Cell: The Patient in Early Sickle Cell Disease Case Reports, 1910-1933." Journal of the National Medical Association vol. 106,1 (0): 31-41. doi: https://doi.org/10.1016/S0027-9684(15)30068-7
Savitt TL. Learning About Sickle Cell: The Patient in Early Sickle Cell Disease Case Reports, 1910-1933. J Natl Med Assoc. Summer 2014;106(1):31-41. doi: 10.1016/S0027-9684(15)30068-7. PMID: 26744113.
Copy Download .nbib Format: NLM
Loss of Mucosal p32/gC1qR/HABP1 Triggers Energy Deficiency and Impairs Goblet Cell Differentiation in Ulcerative Colitis.

Cellular and molecular gastroenterology and hepatology

Sünderhauf A, Hicken M, Schlichting H, Skibbe K, Ragab M, Raschdorf A, Hirose M, Schäffler H, Bokemeyer A, Bettenworth D, Savitt AG, Perner S, Ibrahim S, Peerschke EI, Ghebrehiwet B, Derer S, Sina C.
PMID: 33515804
Cell Mol Gastroenterol Hepatol. 2021;12(1):229-250. doi: 10.1016/j.jcmgh.2021.01.017. Epub 2021 Jan 27.

BACKGROUND & AIMS: Cell differentiation in the colonic crypt is driven by a metabolic switch from glycolysis to mitochondrial oxidation. Mitochondrial and goblet cell dysfunction have been attributed to the pathology of ulcerative colitis (UC). We hypothesized that p32/gC1qR/HABP1,...

Cite
Sünderhauf A, Hicken M, Schlichting H, et al. Loss of Mucosal p32/gC1qR/HABP1 Triggers Energy Deficiency and Impairs Goblet Cell Differentiation in Ulcerative Colitis. Cell Mol Gastroenterol Hepatol. 2021;12(1):229-250doi: 10.1016/j.jcmgh.2021.01.017.
Sünderhauf, A., Hicken, M., Schlichting, H., Skibbe, K., Ragab, M., Raschdorf, A., Hirose, M., Schäffler, H., Bokemeyer, A., Bettenworth, D., Savitt, A. G., Perner, S., Ibrahim, S., Peerschke, E. I., Ghebrehiwet, B., Derer, S., & Sina, C. (2021). Loss of Mucosal p32/gC1qR/HABP1 Triggers Energy Deficiency and Impairs Goblet Cell Differentiation in Ulcerative Colitis. Cellular and molecular gastroenterology and hepatology, 12(1), 229-250. https://doi.org/10.1016/j.jcmgh.2021.01.017
Sünderhauf, Annika, et al. "Loss of Mucosal p32/gC1qR/HABP1 Triggers Energy Deficiency and Impairs Goblet Cell Differentiation in Ulcerative Colitis." Cellular and molecular gastroenterology and hepatology vol. 12,1 (2021): 229-250. doi: https://doi.org/10.1016/j.jcmgh.2021.01.017
Sünderhauf A, Hicken M, Schlichting H, Skibbe K, Ragab M, Raschdorf A, Hirose M, Schäffler H, Bokemeyer A, Bettenworth D, Savitt AG, Perner S, Ibrahim S, Peerschke EI, Ghebrehiwet B, Derer S, Sina C. Loss of Mucosal p32/gC1qR/HABP1 Triggers Energy Deficiency and Impairs Goblet Cell Differentiation in Ulcerative Colitis. Cell Mol Gastroenterol Hepatol. 2021;12(1):229-250. doi: 10.1016/j.jcmgh.2021.01.017. Epub 2021 Jan 27. PMID: 33515804; PMCID: PMC8135049.
Copy Download .nbib Format: NLM
Weight loss and weight gain in Parkinson disease.

Parkinsonism & related disorders

Ghourchian S, Gruber-Baldini AL, Shakya S, Herndon J, Reich SG, von Coelln R, Savitt JM, Shulman LM.
PMID: 33465545
Parkinsonism Relat Disord. 2021 Feb;83:31-36. doi: 10.1016/j.parkreldis.2020.12.018. Epub 2021 Jan 12.

INTRODUCTION: Parkinson disease (PD) has been associated with both weight loss and gain in different stages of the disease. Our study aimed to determine the prevalence and associations with weight change over two years based on 3% and 5%...

Cite
Ghourchian S, Gruber-Baldini AL, Shakya S, et al. Weight loss and weight gain in Parkinson disease. Parkinsonism Relat Disord. 2021;83:31-36doi: 10.1016/j.parkreldis.2020.12.018.
Ghourchian, S., Gruber-Baldini, A. L., Shakya, S., Herndon, J., Reich, S. G., von Coelln, R., Savitt, J. M., & Shulman, L. M. (2021). Weight loss and weight gain in Parkinson disease. Parkinsonism & related disorders, 8331-36. https://doi.org/10.1016/j.parkreldis.2020.12.018
Ghourchian, Shadi, et al. "Weight loss and weight gain in Parkinson disease." Parkinsonism & related disorders vol. 83 (2021): 31-36. doi: https://doi.org/10.1016/j.parkreldis.2020.12.018
Ghourchian S, Gruber-Baldini AL, Shakya S, Herndon J, Reich SG, von Coelln R, Savitt JM, Shulman LM. Weight loss and weight gain in Parkinson disease. Parkinsonism Relat Disord. 2021 Feb;83:31-36. doi: 10.1016/j.parkreldis.2020.12.018. Epub 2021 Jan 12. PMID: 33465545.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 35 entries